Liver transplantation: Difference between revisions
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
Line 29: | Line 29: | ||
Liver transplantation is applicable to any acute or chronic condition resulting in irreversible [[liver]] dysfunction, provided that the recipient does not have other conditions that will preclude a successful [[Organ transplant|transplant]]. Most liver transplants are performed for [[Chronic liver disease|chronic liver diseases]] that lead to irreversible scarring of the [[liver]], or [[cirrhosis]]. | Liver transplantation is applicable to any acute or chronic condition resulting in irreversible [[liver]] dysfunction, provided that the recipient does not have other conditions that will preclude a successful [[Organ transplant|transplant]]. Most liver transplants are performed for [[Chronic liver disease|chronic liver diseases]] that lead to irreversible scarring of the [[liver]], or [[cirrhosis]]. | ||
* The most common indications for liver transplantation in the United States are: | * The most common indications for liver transplantation in the United States are: | ||
** [[Hepatitis C | ** [[Hepatitis C]] | ||
** [[Alcoholic liver disease]] | ** [[Alcoholic liver disease]] | ||
** Idiopathic | ** Idiopathic or autoimmune liver disease | ||
** [[Primary biliary cirrhosis]] | ** [[Primary biliary cirrhosis]] | ||
** [[Primary sclerosing cholangitis]] | ** [[Primary sclerosing cholangitis]] | ||
** [[Hepatitis B | ** [[Hepatitis B]] | ||
** Metabolic [[liver]] disease ( | ** Metabolic [[liver]] disease (e.g. inborn errors of [[metabolism]]) | ||
** [[ | ** [[Carcinoma]] | ||
** [[Biliary atresia]] | ** [[Biliary atresia]] | ||
** [[Acute liver failure]]: | ** [[Acute liver failure]]: | ||
*** Severe acute [[liver]] injury with impaired synthetic function of the [[liver]](INR ≥1.5) and [[encephalopathy]] in the absence of pre existing [[liver]] disease or cirrhosis | *** Severe acute [[liver]] injury with impaired synthetic function of the [[liver]] (INR ≥1.5) and [[encephalopathy]] in the absence of pre existing [[liver]] disease or cirrhosis | ||
*** Common causes: | *** Common causes: | ||
**** [[Virus|Viral]] | **** [[Virus|Viral]] | ||
**** Drug-induced | **** Drug-induced | ||
*** [[Acute liver failure]] has the highest priority for liver transplantation | *** [[Acute liver failure]] has the highest priority for liver transplantation and warrants immediate referral to [[Organ transplant|transplantation]] centre | ||
*** In the absence of [[Organ transplant|transplantation]], [[Patient|patients]] may recover or die | *** In the absence of [[Organ transplant|transplantation]], [[Patient|patients]] may recover or die | ||
** [[Cirrhosis]]: | ** [[Cirrhosis]]: | ||
*** | *** Cirrhosis is an indication only in the presence of complications such as [[portal hypertension]] or compromised [[Liver|hepatic]] function (marker for impaired survival) | ||
*** Signs of decompensated [[cirrhosis]] include: | *** Signs of decompensated [[cirrhosis]] include: | ||
**** [[Ascites]] | **** [[Ascites]] | ||
**** [[Encephalopathy]] | **** [[Encephalopathy]] | ||
**** [[Esophageal varices|Variceal | **** [[Esophageal varices|Variceal hemorrhage]] | ||
**** [[Hepatorenal syndrome]] | **** [[Hepatorenal syndrome]] | ||
*** Transplantation evaluation is commenced in patients with [[MELD Score|MELD score]] >10: | *** Transplantation evaluation is commenced in patients with [[MELD Score|MELD score]] >10: | ||
*** This gives the [[patient]] time for | *** This gives the [[patient]] time for pre transplantation evaluation (as a [[MELD Score|MELD score]] ≥15 is an indication for transplantation) | ||
*** [[Patient]] has ample time for education, before the development of symptoms of [[hepatic encephalopathy]] that may impair cognition | *** [[Patient]] has ample time for education, before the development of symptoms of [[hepatic encephalopathy]] that may impair cognition | ||
*** [[Patient|Patients]] with [[cirrhosis]] are candidates for liver transplantation in the following scenarios: | *** [[Patient|Patients]] with [[cirrhosis]] are candidates for liver transplantation in the following scenarios: | ||
Line 59: | Line 59: | ||
**** Cases of Child B cirrhosis with [[portal hypertension]] but a low [[MELD Score|MELD score]] | **** Cases of Child B cirrhosis with [[portal hypertension]] but a low [[MELD Score|MELD score]] | ||
**** [[MELD Score|MELD]] exception points are given to patients with pathologies that may impair survival without impacting the [[MELD Score|MELD score]] such as: | **** [[MELD Score|MELD]] exception points are given to patients with pathologies that may impair survival without impacting the [[MELD Score|MELD score]] such as: | ||
***** [[Cancer]]: [[Hepatocellular carcinoma|HCC]] | ***** [[Cancer]]: | ||
****** [[Hepatocellular carcinoma|HCC]] | |||
****** [[Cholangiocarcinoma|Hilar cholangiocarcinoma]] | |||
***** Complications of [[cirrhosis]]: | ***** Complications of [[cirrhosis]]: | ||
****** [[Hepatopulmonary syndrome]] | ****** [[Hepatopulmonary syndrome]] | ||
Line 66: | Line 68: | ||
****** [[Hepatic artery]] [[thrombosis]] | ****** [[Hepatic artery]] [[thrombosis]] | ||
***** [[Cystic fibrosis]]: | ***** [[Cystic fibrosis]]: | ||
***** [[Primary hyperoxaluria]] | |||
***** [[Familial amyloid polyneuropathy]] | |||
***** Other | ***** Other indications for transplantation that do not qualify for [[MELD Score|MELD]] or [[MELD Score|MELD]] exception points include: | ||
****** Intractable [[Itch|pruritus]] in case of [[primary biliary cirrhosis]] | ****** Intractable [[Itch|pruritus]] in case of [[primary biliary cirrhosis]] | ||
****** Refractory [[Esophageal varices|variceal | ****** Refractory [[Esophageal varices|variceal hemorrhage]] | ||
****** Refractory [[ascites]] | ****** Refractory [[ascites]] | ||
****** Refractory [[hepatic encephalopathy]] | ****** Refractory [[hepatic encephalopathy]] | ||
****** [[Portal hypertensive gastropathy]] leading to chronic [[blood]] loss | ****** [[Portal hypertensive gastropathy]] leading to chronic [[blood]] loss | ||
****** Recurrent [[cholangitis]] in patients with [[Primary sclerosing cholangitis|PSC]] | ****** Recurrent [[cholangitis]] in patients with [[Primary sclerosing cholangitis|PSC]] | ||
****** [[Hepatocellular carcinoma|HCC]]: | ****** [[Hepatocellular carcinoma|HCC]]: | ||
******* A single lesion ≤5 cm or up to three separate [[Lesion|lesions]] all <3 cm | |||
******* No evidence of gross [[vascular]] invasion, and | |||
******* No regional [[Lymph node|nodal]] or distant [[metastasis]] | |||
****** [[Neuroendocrine tumors]] that have metastasized to the [[liver]] | ****** [[Neuroendocrine tumors]] that have metastasized to the [[liver]] | ||
****** [[Hepatocellular carcinoma|HCC]] (including fibrolamellar [[Hepatocellular carcinoma|HCC]]) | ****** [[Hepatocellular carcinoma|HCC]] (including fibrolamellar [[Hepatocellular carcinoma|HCC]]) | ||
****** Large [[Hepatocellular adenoma|hepatic adenomas]] | ****** Large [[Hepatocellular adenoma|hepatic adenomas]] | ||
****** Epithelioid hemangioendothelioma | ****** [[Hemangioendothelioma|Epithelioid hemangioendothelioma]] | ||
****** [[Metabolic disorder|Metabolic disorders]]: | ****** [[Metabolic disorder|Metabolic disorders]]: | ||
******* [[Alpha 1-antitrypsin deficiency|Alpha-1 antitrypsin deficiency]] | ******* [[Alpha 1-antitrypsin deficiency|Alpha-1 antitrypsin deficiency]] | ||
******* [[Wilson's disease|Wilson disease]] | ******* [[Wilson's disease|Wilson disease]] | ||
******* [[Acute intermittent porphyria]] | ******* [[Acute intermittent porphyria]] | ||
******* [[Glycogen storage disease]] (type I and type IV) | ******* [[Glycogen storage disease]] ([[Glycogen storage disease type I|type I]] and type IV) | ||
******* [[Tyrosinemia]] | ******* [[Tyrosinemia]] | ||
******* [[Hemochromatosis]] | ******* [[Hemochromatosis]] |
Revision as of 19:12, 25 January 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sudarshana Datta, MD [2]
Overview
When a healthy liver allograft is used in place of damaged liver tissue, it is termed as liver transplantation. Thomas Starzl used dogs as the first animals for research on liver transplantation in the 1960s. In 1963, the first liver transplant in humans was attempted by Dr. Thomas Starzl of Colorado, United States. The most common indications for liver transplantation in the United States are hepatitis C virus, alcoholic liver disease, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, hepatitis B virus, liver disease due to inborn errors of metabolism, cancer, biliary atresia and acute liver failure. On the other hand, absolute contraindications to liver transplantation include hepatocellular carcinoma with metastasis, acute liver failure with persistently elevated intracranial pressure ICP >50mmHg, hemangiosarcoma, hilar cholangiocarcinoma, sepsis, and active alcohol or drug abuse. Pretransplant measures such as cardiopulmonary evaluation, screening for occult cancer, infection, and psychosocial evaluation must be performed prior to surgery. The most commonly used technique employed in patients is orthotopic transplantation. This involves removal of the native liver and placement of the donor organ in the same anatomic location as the original liver. Immunosuppressive agents used after transplantation include cyclosporine, everolimus, mycophenolate, corticosteroids, azathioprine, and tacrolimus in different combinations. The most common causes of death in liver transplant patients are infection, malignancy, and rejection. It is necessary to monitor patients for signs of complications and treat them effectively.
Liver Transplantation
History
- In the 1960s, Thomas Starzl used dogs as the first animals for research on liver transplantation in Boston and Chicago.
- In 1963, the first liver transplant in humans was attempted by a surgical team led by Dr. Thomas Starzl of Denver, Colorado, United States.[1]
- Dr. Starzl performed many additional transplants until he was successful in 1967 with the first one-year survival post-transplantation.
- In 1970, the regimen for immunosuppressive therapy following transplant was introduced, but azathioprine and steroids did not improve survival rates of patients.
- In the 1980s, with the introduction of cyclosporine by Sir Roy Calne, there was an improvement in rejection rates.
- In 1983, liver transplantation was no longer an experimental modality, but a clinically acceptable form of therapy for both adult and pediatric patients with appropriate indications.
- In 1986, the introduction of monoclonal antibodies such as muromonab-CD3 [OKT3] further contributed to improvement of quality of immunosuppressive therapy used in patients, with significant decline in rejection rates.
- In 1988, University of Wisconsin (UW) solution was developed, which ensured a smooth surgery and longer preservation period.
- In 1992, the concept of xenotransplantation and cloning techniques were introduced by Starzl.
- In 1999, approximately 5000 procedures were carried out, in contrast to 100 which had been performed a decade earlier.
- Recently, the introduction of newer immunosuppressive agents such as IL-2 receptor blockers and tacrolimus, have drastically increased patient survival rates to 1 and 5-year rates of approximately 85 and 70 percent respectively.[2]
- Liver transplantation is now performed at over one hundred centers in the USA, as well as numerous centers in Europe and elsewhere. One year patient survival is 85-90%, and outcomes continue to improve, although liver transplantation remains a formidable procedure with frequent complications.
- Unfortunately, the supply of liver allografts from non-living donors is far short of the number of potential recipients, a reality that has spurred the development of living donor liver transplantation.
- In December 2016, 147,128 liver transplants were performed in the US as compared to 7217 in 1998 based on data from the United Organ Sharing (UNOS) network.
Indications
Liver transplantation is applicable to any acute or chronic condition resulting in irreversible liver dysfunction, provided that the recipient does not have other conditions that will preclude a successful transplant. Most liver transplants are performed for chronic liver diseases that lead to irreversible scarring of the liver, or cirrhosis.
- The most common indications for liver transplantation in the United States are:
- Hepatitis C
- Alcoholic liver disease
- Idiopathic or autoimmune liver disease
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Hepatitis B
- Metabolic liver disease (e.g. inborn errors of metabolism)
- Carcinoma
- Biliary atresia
- Acute liver failure:
- Severe acute liver injury with impaired synthetic function of the liver (INR ≥1.5) and encephalopathy in the absence of pre existing liver disease or cirrhosis
- Common causes:
- Viral
- Drug-induced
- Acute liver failure has the highest priority for liver transplantation and warrants immediate referral to transplantation centre
- In the absence of transplantation, patients may recover or die
- Cirrhosis:
- Cirrhosis is an indication only in the presence of complications such as portal hypertension or compromised hepatic function (marker for impaired survival)
- Signs of decompensated cirrhosis include:
- Transplantation evaluation is commenced in patients with MELD score >10:
- This gives the patient time for pre transplantation evaluation (as a MELD score ≥15 is an indication for transplantation)
- Patient has ample time for education, before the development of symptoms of hepatic encephalopathy that may impair cognition
- Patients with cirrhosis are candidates for liver transplantation in the following scenarios:
- Biologic Model for End-stage Liver Disease (MELD) score is ≥15
- Cases of Child B cirrhosis with portal hypertension but a low MELD score
- MELD exception points are given to patients with pathologies that may impair survival without impacting the MELD score such as:
- Cancer:
- Complications of cirrhosis:
- Vascular pathologies:
- Cystic fibrosis:
- Primary hyperoxaluria
- Familial amyloid polyneuropathy
- Other indications for transplantation that do not qualify for MELD or MELD exception points include:
- Intractable pruritus in case of primary biliary cirrhosis
- Refractory variceal hemorrhage
- Refractory ascites
- Refractory hepatic encephalopathy
- Portal hypertensive gastropathy leading to chronic blood loss
- Recurrent cholangitis in patients with PSC
- HCC:
- A single lesion ≤5 cm or up to three separate lesions all <3 cm
- No evidence of gross vascular invasion, and
- No regional nodal or distant metastasis
- Neuroendocrine tumors that have metastasized to the liver
- HCC (including fibrolamellar HCC)
- Large hepatic adenomas
- Epithelioid hemangioendothelioma
- Metabolic disorders:
Contraindications
Absolute contraindications: [3]
- Metastasis outside the liver, past the curative stage
- Hepatocellular carcinoma with metastasis (Stage 1V)
- Acute Liver Failure with persistently elevated intracranial pressure ICP >50mmHg( due to hepatic encephalopathy)
- Hemangiosarcoma
- Hilar cholangiocarcinoma with liver involvement
- Sepsis
- Active alcohol or drug abuse
- Anatomic anomalies that may be a deterrent to transplantation
- Poor adherence to medical treatment
- Absence of social support
Relative contraindications:[3][4][5][6][7][8][9][10][11][12][13]
- Infection with HIV (AIDS)
- Age >65 years
- Any serious pathologies of the lung or heart that cannot be corrected
- BMI ≥40
- Alcoholic liver disease:Only performed if abstinent for ≥ 6 months
- Presence of social support
- Participation in an alcohol abstinence and rehabilitation program
Patient evaluation prior to transplantation
Pre-transplant patient evaluation has the following objectives:
- Assesment of ability of the patient to withstand surgery
- Assesment of ability of the patient to withstand immunosuppression
- Assessment of patients demands of post-transplantation care
The following evaluations are required:
- Cardiopulmonary
- Screening for occult cancer
- Screening for occult infection
- Psychosocial evaluation
Laboratory investigations
Laboratory essential for patient evaluation prior to liver transplantation are as follows:
- Liver function tests:
- Bilirubin levels
- ALT levels
- AST levels
- ALP levels
- International normalized ratio [INR]
- ABO-Rh blood typing
- Calcium levels
- Vitamin D levels
- Complete blood count
- Creatinine clearance
- Serum Na levels
- Serum alpha-fetoprotein
- Serology:
- Urinalysis
- Urine drug screen
Cardiopulmonary evaluation
This helps in the evaluation of the patient for:[3][14]
- The following tests are included:[3][20][21]
- Pulse oximetry is used for the following conditions:[22]
- Screening for hepatopulmonary syndrome: indicates worse prognosis in cirrhotic patients and qualifies patients for standard Model for End-stage Liver Disease (MELD) exception points
- Hepatopulmonary syndrome is characterized by the following:
- Liver disease
- Intrapulmonary vascular dilatations
- Impaired oxygenation
- Hepatopulmonary syndrome is characterized by the following:
- Arterial blood gas: performed in patients with normal pulse oximetry in order to calculate age-adjusted alveolar-arterial gradient
- Chest imaging
- Pulmonary function testing
- Electrocardiogram:
- This helps detect the presence of the following conditions:
- Cardiac arrhythmias
- Conduction defects
- Signs of the following:
- Hypertrophy of the cardiac chamber
- Prior cardiac ischemia
- Cardiac stress testing:[23]
- Noninvasive cardiac testing is performed in the following cases:
- Patients older than 40 years of age
- Patients younger than forty years of age, with multiple risk factors for coronary artery disease
- Noninvasive cardiac testing is performed in the following cases:
- If cardiac stress testing shows abnormalities, the patient undergoes cardiac catheterization.
- In case of presence of clinically significant coronary artery stenosis, revascularization before transplantation is considered.
- Echocardiography:
- Transthoracic contrast-enhanced echocardiography:
- Valvular heart disease
- Suspected cases of hepatopulmonary syndrome: if the oxygen saturation on pulse oximetry is low (<96 percent)
- Portopulmonary hypertension: Pulmonary arterial hypertension (PAH) associated with portal hypertension
Cancer screening
HCC: For tumor staging, investigations include:
- For assessment of vasculature:
- Multiphase contrast-enhanced CT scanning
- Contrast-enhanced MRI
- Transabdominal ultrasonography with Doppler imaging
- Contrast-enhanced ultrasonography
- Skin cancer:
- Skin examination
- Colon cancer:
- Colonoscopy done in case of:
- Age of 50 years
- History of colon cancer in a first-degree relative
- Patients with primary sclerosing cholangitis
- Colonoscopy done in case of:
- Screening for:
Upper GI endoscopy
Purpose: detection of varices
Bone densitometry
- Screening for osteoporosis
- Patients are treated with bisphosphonates before transplanatation
Vaccinations and evaluation for infection
- Workup for tuberculosis:
- Skin testing
- Interferon-gamma release assay
- Screening in endemic areas for:
- Vaccinations recommended before liver transplantation include:
Psychosocial evaluation and education
- Discussion of risks and benefits of transplantation
- Ensuring social support
- Substance use disorders eg alcohol must be treated prior to transplantation:
- Rehabilitation
- Abstinence program
- Education of the family
- Patient compliance with elaborate behavioral and medical regimens
Techniques
- Before transplantation, liver support therapy might be indicated ( called bridging-to-transplantation).
- Artificial liver support like liver dialysis or bioartificial liver support concepts are currently under preclinical and clinical evaluation.
- Virtually all liver transplants are done in an orthotopic fashion, that is the native liver is removed and the new liver is placed in the same anatomic location.
- The transplant operation may be conceptualized as consisting of:[24][25][26][27][3]
- Hepatectomy (liver removal) phase
- Anhepatic (no liver) phase
- Postimplantation phase
- The operation is done through a large incision in the upper abdomen.
- The hepatectomy involves division of:[28][29]
- All ligamentous attachments to the liver
- Common bile duct
- Hepatic artery
- Portal vein
- Usually, the retrohepatic portion of the inferior vena cava is removed along with the liver, although an alternative technique preserves the recipient's vena cava ("piggyback" technique).
- The donor's blood in the liver is replaced by an ice-cold organ storage solution, such as UW (Viaspan) or HTK until the allograft liver is implanted.
- Implantation involves anastomoses (connections) of the inferior vena cava, portal vein, and hepatic artery.
- After blood flow is restored to the new liver, the biliary (bile duct) anastomosis is constructed, either to the recipient's own bile duct or to the small intestine.
- The surgery usually takes between five and six hours, but may be longer or shorter due to the difficulty of the operation and the experience of the surgeon.
- The large majority of liver transplants use the entire liver from a non-living donor for the transplant, particularly for adult recipients.[30][31]
- A major advance in pediatric liver transplantation was the development of reduced size liver transplantation, in which a portion of an adult liver is used for an infant or small child.
- Further developments in this area included split liver transplantation, in which one liver is used for transplants for two recipients, and living donor liver transplantation, in which a portion of healthy person's liver is removed and used as the allograft.
- Living donor liver transplantation for pediatric recipients involves removal of approximately 20% of the liver (Couinaud segments 2 and 3).
{{#ev:youtube|v=hquWw4rRHh8}}
Orthotopic Liver Transplantation
- Donor selection based on biomarkers and risk indices is a crucial aspect of orthotopic liver transplantation and involves:
- Preference of younger to older donors
- Appropriate selection of recipients
- Age based matching of donors and recipients
- Surgery involves the following steps:[32][33][34]
- Excision of the liver of the recipient
- Separation of:
- During surgery, venovenous bypass helps in diversion of flow from disrupted Inferior Vena Cava (IVC) and portal vein to Superior Vena Cava (SVC).
- In order to maintain blood flow of the hepatic artery, anastomosis of donor liver at vascular sites is done.
- Anastomosis of the bile ducts of the graft and recipient is performed.
- In addition, choledochojejunostomy may also be performed.
- Postoperatively, stenting of the bile duct using a T-tube may help monitor:
Immunosuppressive management
- Postimplant immunosuppression ensures survival of the patient and allograft.
- Immunosuppressive agents used in patients receiving a liver transplant include the following:[35][36]
- Agents used for induction therapy include:
- High-dose corticosteroids
- Antithymocyte globulin
- Monoclonal antibody
- Azathioprine
- Cyclosporine/Tacrolimus (calcineurin inhibitors)
- Antiproliferative agents
- Agents for long-term immunosuppression:
- The risk of chronic rejection in patients with liver transplantation decreases with time,although recipients may need to take immunosuppresive therapy for the rest of their lives.
Results
- Prognosis is quite good:[37][38][39][40][41]
- 1-year survival is 83%
- 5-year survival is 76%
- 10-year survival is 66%
- Majority of deaths happen during the first three months after transplantation.
Living donor transplantation
- Living donor liver transplantation (LDLT) has emerged in recent decades as a critical surgical option for patients with end stage liver disease, such as cirrhosis and/or hepatocellular carcinoma often attributable to one or more of the following:[29][42][43]
- Long-term alcohol abuse
- Long-term untreated Hepatitis C infection
- Long-term untreated Hepatitis B infection
- The concept of LDLT is based on:
- Remarkable regenerative capacities of the human liver
- Widespread shortage of cadaveric livers for patients awaiting transplant
- In LDLT, a piece of healthy liver is surgically removed from a living person and transplanted into a recipient, immediately after the recipient’s diseased liver has been entirely removed.
- Historically, LDLT was used as a means for parents of children with severe liver disease to donate a portion of their healthy liver to replace the damaged liver of their children.
- In 1986, the first successful LDLT was performed at the Universidade de São Paulo (USP) Medical School, by Dr. Silvano Raia.
- More technically demanding than standard, cadaveric donor liver transplantation
- Has faced several ethical problems[44]
Complications of Liver Transplantation
- Complications that may develop in transplant recipients include the following:[45]
- Acute rejection of the graft
- Adverse effects of immunosuppressive therapy
- Biliary stricture
- Biliary leak
- Vascular thrombosis
- Sepsis
- Malignancy
- Immediate postoperative complications of liver transplantation include:
- The most common causes of death in liver transplant patients are as follows:
- To monitor the patient for complications, the following investigations are used:
Laboratory investigations
- The following laboratory investigations help in providing evidence of rejection, and also help in the assessment of drugs( Azathioprine, Cyclosporine and Tacrolimus) along with their effect on bone marrow and renal function:
- CBC
- Electrolyte panel
- Liver function tests
- Kidney function tests (KFTs)
- Drug levels in case of altered Kidney Function Tests, or suspected rejection:
- Cyclosporine levels
- Tacrolimus levels
- In case of suspected infection:
Imaging studies
- Chest radiography:
- Abdominal ultrasonography
- Computed tomography scan
- Endoscopic retrograde cholangiopancreatography (ERCP)
Acute and chronic graft rejection
- Vigilance is required for detection of rejection due to subtle presentations.
- Occurrence: roughly 20-70 percent patients
- Timing: 1-2 weeks post- transplantation, within first three months of transplantation
- Outcome: Graft dysfunction
- Clinical presentation:
- Jaundice
- Fever
- Right-upper-quadrant tenderness
- Generalized abdominal tenderness
- Eosinophilia
- In case of mild rejection, symptoms may be nonspecific and include:
- Laboratory evidence:
- Abnormal liver function tests
- Elevated Bilirubin
- Elevated alkaline phosphatase levels
- Elevation of hepatocellular enzymes:
- Treatment of acute rejection:[46]
- High-dose steroids:
- Prednisolone 200 mg
- Methylprednisolone 1 g for 3 days)
- High-dose steroid bolus followed by a rapid taper over 1 week
- High-dose steroids:
- Alternative therapies include:
- Antibody treatments:
- Monoclonal therapy (OKT3 )
- Antithymocyte globulin
- Antibody treatments:
- Occurence: 5% of patients
- Main cause of late stage graft failure
- Features of chronic graft rejection include:
- Gradual obliteration of small bile ducts
- Microvascular changes
- Symptoms:
- Laboratory investigations:
- Elevated serum alkaline phosphatase
- Elevated bilirubin levels
- Gold standard diagnostic modality: Liver biopsy
Infection
Infections may be classified based on the duration post transplantation.
- <1 month : Common conditions developing in patients in the early posttransplant period include intra-abdominal infections such as:
- 1-6 months: Infections commonly occur due to:
- After the first 6 months, risk of infection in transplant patients is equal to that of the population.
- Infection is primarily nosocomial. Common organisms responsible for causing infection post-transplant are as follows:[47]
- Bacterial (most common):
- Enterococci
- Staphylococci
- Gram-negative aerobes
- Anaerobes
- Fungal: Candida (75% of fungal infections)
- Presenting symptoms: may be non specific [45]
- Fever (absent or low grade)
- Abdominal pain
- Jaundice
- Masking of symptoms may occur due to immunosuppression
- Minimal pain at infection site
- Bacterial (most common):
- Laboratory investigations:
- Complete blood count (CBC)
- Serum chemistries
- Liver function tests
- Coagulation panel
- Urinalysis
- Urine culture
- Blood culture
- Imaging:
- Abdominal radiographs
- Chest radiographs
- Computed tomography (CT)
- Abdominal ultrasonography
- T-tube cholangiography
- Endoscopic retrogrande cholangiopancreatography (ERCP)
- Liver biopsy
- Treatment of infection: [48]
- Antimicrobials prescribed for non-immunosuppressed patients
Cytomegalovirus (CMV)
- Most common viral infection (affects 25-85% patients)
- Occurrence: Between posttransplant months 1 and 3
- Infection may be:
- Primary
- Reactivated
- Clinical presentation:
- Fever
- Malaise
- Arthralgias
- Laboratory investigations:
- Atypical lymphocytes
- Thrombocytopenia
- Mildly elevated transaminase levels
- Imaging findings:
- CXR: CMV pneumonitis patients may have bilateral infiltrates on CXR
- Serology: Indirect immunofluorescence testing method
- Treatment: Ganciclovir intravenously for 2-4 weeks
Pneumocystis carinii pneumonia (PCP)
- May occur along with CMV infection or alone
- Diagnosis: Bronchoalveolar biopsy
- Treatment: Trimethoprim-sulfamethoxazole
Other less common organisms causing infection include:
- Fungi (especially Candida species)
- Herpes simplex
- Herpes zoster
- Toxoplasma
- Hepatitis C virus (HCV)
- Hepatitis B infection
- Malignancy:
- In transplant patients, malignancy is the second leading cause of late mortality.
- Common malignancies occuring in patients after transplantation include:
- Lymphomas
- Squamous cell carcinoma : SCC of skin is the most common malignancy that occurs pos-tranplantation
- Posttransplant lymphoproliferative disorder
External Links
- American Liver Foundation: Comprehensive information about Hepatitis C, Liver Transplant and other liver diseases, including links to chapters for finding local resources
- Management of HBV Infection in Liver Transplantation Patients
- Management of HCV Infection and Liver Transplantation
- Antiviral therapy of HCV in the cirrhotic and transplant candidate
- Living Donors Online
- Liver Donor
- History of pediatric liver transplantation
- ABC Salutaris: Living Donor Liver Transplant
- Organ Donation Awareness and former potential donor blog
- All You Need to Know about Adult Living Donor Liver Transplantation
References
- ↑ STARZL T, MARCHIORO T, VONKAULLA K, HERMANN G, BRITTAIN R, WADDELL W. "HOMOTRANSPLANTATION OF THE LIVER IN HUMANS". Surg Gynecol Obstet. 117: 659–76. PMID 14100514.
- ↑ Kanwal F, Dulai GS, Spiegel BM, Yee HF, Gralnek IM (2005). "A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras". Aliment. Pharmacol. Ther. 21 (2): 169–77. doi:10.1111/j.1365-2036.2005.02321.x. PMID 15679767.
- ↑ 3.0 3.1 3.2 3.3 3.4 Martin P, DiMartini A, Feng S, Brown R, Fallon M (2014). "Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation". Hepatology. 59 (3): 1144–65. PMID 24716201.
- ↑ Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC (2011). "Early liver transplantation for severe alcoholic hepatitis". N. Engl. J. Med. 365 (19): 1790–800. doi:10.1056/NEJMoa1105703. PMID 22070476.
- ↑ Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ (2011). "Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort". AIDS. 25 (6): 777–86. doi:10.1097/QAD.0b013e328344febb. PMID 21412058.
- ↑ Mindikoglu AL, Regev A, Magder LS (2008). "Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database". Transplantation. 85 (3): 359–68. doi:10.1097/TP.0b013e3181605fda. PMID 18301332.
- ↑ Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Millis JM, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG (2012). "Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection". Liver Transpl. 18 (6): 716–26. doi:10.1002/lt.23411. PMC 3358510. PMID 22328294.
- ↑ Cross TJ, Antoniades CG, Muiesan P, Al-Chalabi T, Aluvihare V, Agarwal K, Portmann BC, Rela M, Heaton ND, O'Grady JG, Heneghan MA (2007). "Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival". Liver Transpl. 13 (10): 1382–8. doi:10.1002/lt.21181. PMID 17902123.
- ↑ Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O'Grady J, Rela M, Heaton ND (2001). "Liver transplantation in adults coinfected with HIV". Transplantation. 72 (10): 1684–8. PMID 11726833.
- ↑ Wreghitt T (2001). "Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684". Transplantation. 72 (10): 1594–5. PMID 11726816.
- ↑ Stock P, Roland M, Carlson L, Freise C, Hirose R, Terrault N, Frassetto L, Coates T, Roberts J, Ascher N (2001). "Solid organ transplantation in HIV-positive patients". Transplant. Proc. 33 (7–8): 3646–8. PMID 11750549.
- ↑ Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL (2003). "Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study". Transplantation. 76 (2): 370–5. doi:10.1097/01.TP.0000075973.73064.A6. PMID 12883195.
- ↑ Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, Fung JJ (2003). "Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease". Liver Transpl. 9 (3): 239–47. doi:10.1053/jlts.2003.50054. PMID 12619020.
- ↑ Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE (2003). "Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation". Am. J. Cardiol. 92 (9): 1066–71. PMID 14583357.
- ↑ Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, Neuhaus P, Langrehr JM (2006). "Validation of cardiovascular risk scores in a liver transplant population". Liver Transpl. 12 (3): 394–401. doi:10.1002/lt.20722. PMID 16498651.
- ↑ Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y (1996). "Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation". Liver Transpl Surg. 2 (6): 426–30. PMID 9346688.
- ↑ Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, Valla D, Durand F (2003). "Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study". Hepatology. 37 (2): 401–9. doi:10.1053/jhep.2003.50060. PMID 12540791.
- ↑ Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, Pardo M, Marotta P, Uemoto S, Stoffel MP, Benson JT (2004). "Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database". Liver Transpl. 10 (2): 174–82. doi:10.1002/lt.20016. PMID 14762853.
- ↑ Starkel P, Vera A, Gunson B, Mutimer D (2002). "Outcome of liver transplantation for patients with pulmonary hypertension". Liver Transpl. 8 (4): 382–8. doi:10.1053/jlts.2002.31343. PMID 11965583.
- ↑ Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA (2012). "Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation". J. Am. Coll. Cardiol. 60 (5): 434–80. doi:10.1016/j.jacc.2012.05.008. PMID 22763103.
- ↑ Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, Fix OK, Kay N, Abecassis MI, Gheorghiade M, Flaherty JD (2011). "Cardiovascular risk assessment of the liver transplant candidate". J. Am. Coll. Cardiol. 58 (3): 223–31. doi:10.1016/j.jacc.2011.03.026. PMID 21737011.
- ↑ Arguedas MR, Singh H, Faulk DK, Fallon MB (2007). "Utility of pulse oximetry screening for hepatopulmonary syndrome". Clin. Gastroenterol. Hepatol. 5 (6): 749–54. doi:10.1016/j.cgh.2006.12.003. PMID 17392034.
- ↑ Prentis JM, Manas DM, Trenell MI, Hudson M, Jones DJ, Snowden CP (2012). "Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation". Liver Transpl. 18 (2): 152–9. doi:10.1002/lt.22426. PMID 21898768.
- ↑ Eghtesad B, Kadry Z, Fung J (2005). "Technical considerations in liver transplantation: what a hepatologist needs to know (and every surgeon should practice)". Liver Transpl. 11 (8): 861–71. doi:10.1002/lt.20529. PMID 16035067.
- ↑ Tuttle-Newhall JE, Collins BH, Desai DM, Kuo PC, Heneghan MA (2005). "The current status of living donor liver transplantation". Curr Probl Surg. 42 (3): 144–83. PMID 15859440.
- ↑ Steadman RH (2004). "Anesthesia for liver transplant surgery". Anesthesiol Clin North America. 22 (4): 687–711. doi:10.1016/j.atc.2004.06.009. PMID 15541931.
- ↑ Park JI, Kim KH, Lee SG (2015). "Laparoscopic living donor hepatectomy: a review of current status". J Hepatobiliary Pancreat Sci. 22 (11): 779–88. doi:10.1002/jhbp.288. PMID 26449392.
- ↑ Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E (2003). "Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry". Liver Transpl. 9 (12): 1231–43. doi:10.1016/j.lts.2003.09.018. PMID 14625822.
- ↑ 29.0 29.1 Shah SA, Levy GA, Adcock LD, Gallagher G, Grant DR (2006). "Adult-to-adult living donor liver transplantation". Can. J. Gastroenterol. 20 (5): 339–43. PMC 2659892. PMID 16691300.
- ↑ Reddy S, Zilvetti M, Brockmann J, McLaren A, Friend P (2004). "Liver transplantation from non-heart-beating donors: current status and future prospects". Liver Transpl. 10 (10): 1223–32. doi:10.1002/lt.20268. PMID 15376341.
- ↑ Martinez OM, Rosen HR (2005). "Basic concepts in transplant immunology". Liver Transpl. 11 (4): 370–81. doi:10.1002/lt.20406. PMID 15776458.
- ↑ Friend PJ (1997). "Liver transplantation". Transplant. Proc. 29 (6): 2716–8. PMID 9290801.
- ↑ McCaughan GW, Koorey DJ (1997). "Liver transplantation". Aust N Z J Med. 27 (4): 371–8. PMID 9448876.
- ↑ Middleton PF, Duffield M, Lynch SV, Padbury RT, House T, Stanton P, Verran D, Maddern G (2006). "Living donor liver transplantation--adult donor outcomes: a systematic review". Liver Transpl. 12 (1): 24–30. PMID 16498709.
- ↑ Perry I, Neuberger J (2005). "Immunosuppression: towards a logical approach in liver transplantation". Clin. Exp. Immunol. 139 (1): 2–10. doi:10.1111/j.1365-2249.2005.02662.x. PMC 1809260. PMID 15606606.
- ↑ Papadopoulos-Köhn A, Achterfeld A, Paul A, Canbay A, Timm J, Jochum C, Gerken G, Herzer K (2015). "Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant". Transplantation. 99 (4): 841–7. doi:10.1097/TP.0000000000000399. PMID 25208324.
- ↑ Chen XB, Xu MQ (2014). "Primary graft dysfunction after liver transplantation". HBPD INT. 13 (2): 125–37. PMID 24686540.
- ↑ Liu JH, Yan S, Zheng SS (2014). "[Application of transient elastography in early prognosis after liver transplantation]". Zhejiang Da Xue Xue Bao Yi Xue Ban (in Chinese). 43 (6): 678–82. PMID 25644567.
- ↑ Lindström L, Jørgensen KK, Boberg KM, Castedal M, Rasmussen A, Rostved AA, Isoniemi H, Bottai M, Bergquist A (2018). "Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study". Scand. J. Gastroenterol.: 1–8. doi:10.1080/00365521.2017.1421705. PMID 29301479.
- ↑ Germani G, Becchetti C (2017). "Liver transplantation for non-alcoholic fatty liver disease". Minerva Gastroenterol Dietol. doi:10.23736/S1121-421X.17.02467-9. PMID 29249127.
- ↑ Egeli T, Unek T, Ozbilgin M, Agalar C, Derici S, Akarsu M, Unek IT, Aysin M, Bacakoglu A, Astarcıoglu I (2017). "De Novo Malignancies After Liver Transplantation: A Single Institution Experience". Exp Clin Transplant. doi:10.6002/ect.2017.0111. PMID 29237362.
- ↑ Nadalin S, Capobianco I, Panaro F, Di Francesco F, Troisi R, Sainz-Barriga M, Muiesan P, Königsrainer A, Testa G (2016). "Living donor liver transplantation in Europe". Hepatobiliary Surg Nutr. 5 (2): 159–75. doi:10.3978/j.issn.2304-3881.2015.10.04. PMC 4824742. PMID 27115011.
- ↑ Brown RS, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, Hoofnagle JH (2003). "A survey of liver transplantation from living adult donors in the United States". N. Engl. J. Med. 348 (9): 818–25. doi:10.1056/NEJMsa021345. PMID 12606737.
- ↑ Krahn LE, DiMartini A (2005). "Psychiatric and psychosocial aspects of liver transplantation". Liver Transpl. 11 (10): 1157–68. doi:10.1002/lt.20578. PMID 16184540.
- ↑ 45.0 45.1 45.2 Savitsky EA, Uner AB, Votey SR (1998). "Evaluation of orthotopic liver transplant recipients presenting to the emergency department". Ann Emerg Med. 31 (4): 507–17. PMID 9546022.
- ↑ Levitsky J, Cohen SM (2006). "The liver transplant recipient: what you need to know for long-term care". J Fam Pract. 55 (2): 136–44. PMID 16451781.
- ↑ Greendyke WG, Pereira MR (2016). "Infectious Complications and Vaccinations in the Posttransplant Population". Med. Clin. North Am. 100 (3): 587–98. doi:10.1016/j.mcna.2016.01.008. PMID 27095647.
- ↑ Muñoz SJ (1996). "Long-term management of the liver transplant recipient". Med. Clin. North Am. 80 (5): 1103–20. PMID 8804376.
Template:Organ transplantation
Template:Digestive system surgical procedures
bg:Чернодробна трансплантация de:Lebertransplantation it:Trapianto di fegato he:השתלת כבד nl:Levertransplantatie fi:Maksansiirto